Viridian Therapeutics, Inc.

VRDN

US92790C1045

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 17/07/2024 am IST			5-day change	1st Jan Change
15.97 ^USD	+8.71%		+29.42%	-26.68%

11/06	Sector Update: Health Care Stocks Mixed Premarket Tuesday	MT
11/06	Sector Update: Health Care	MT

Viridian Therapeutics, Inc. Appoints Jonathan Violin, as Chief Executive Officer

January 20, 2021 at 06:32 pm IST

Viridian Therapeutics, Inc. announced the appointment of Jonathan Violin, as Chief Executive Officer and Principal Executive Officer of the Company, effective as of January 15, 2021.

Latest news about Viridian Therapeutics, Inc.

Sector Update: Health Care Stocks Mixed Premarket Tuesday	11/06	MT
Sector Update: Health Care	11/06	MT
Transcript : Viridian Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:40 AM	11/06
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday as US FOMC Meeting Begins	11/06	MT
Wolfe Research Initiates Coverage on Viridian Therapeutics With Outperform Rating, $29 Price Target	11/06	MT
Viridian Therapeutics Plans Two Late-Stage Trials of VRDN-003 in Thyroid Eye Disease -- Shares Advance Premarket	11/06	MT
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-To-Severe Thyroid Eye Disease	11/06	CI
Goldman Sachs Initiates Coverage on Viridian Therapeutics With Buy Rating, $23 Price Target	06/06	MT
Transcript : Viridian Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 04:35 PM	16/05
Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating	09/05	MT
B. Riley Downgrades Viridian Therapeutics to Neutral From Buy	09/05	MT
B. Riley Downgrades Viridian Therapeutics to Neutral From Buy, Cuts Price Target to $20 From $25	09/05	MT
Wedbush Raises Viridian Therapeutics Price Target to $42 From $40, Maintains Outperform Rating	08/05	MT
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Reports Q1 Revenue $72,000	08/05	MT
Transcript : Viridian Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024	08/05
Viridian Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Foghorn Therapeutics Names Kristian Humer CFO	16/04	MT
B. Riley Lowers Viridian Therapeutics' PT to $25 From $29, Keeps Buy Rating; Adjusts Model to Reflect Recent Equity Offering, Quarterly Numbers	21/03	MT
Wedbush Lifts Viridian Therapeutics' PT to $40 From $39 on Higher Net Cash, Keeps Outperform Rating	28/02	MT
Viridian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Viridian Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02	CI
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Posts Q4 Revenue $72,000	28/02	MT
Viridian Therapeutics Names Jennifer Tousignant as Chief Legal Officer	17/02	MT
Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer	16/02	CI
Wedbush Trims Viridian Therapeutics' Price Target to $39 From $40, Keeps Outperform Rating	22/01	MT

Chart Viridian Therapeutics, Inc.

Duration

Period

More charts

Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. It is focused on advancing VRDN-001 as a potential intravenous therapy followed by VRDN-003 as a potential subcutaneous therapy for the treatment of TED. Its advanced program, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Viridian Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

15.97 USD

Average target price

35.19 USD

Spread / Average Target

+120.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VIRIDIAN THERAPEUTICS, INC.	-26.68%	1.02B
MODERNA, INC.	+25.83%	47.96B
LONZA GROUP AG	+45.38%	41.47B
IQVIA HOLDINGS INC.	+0.69%	42.45B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	31.6B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.56B
MEDPACE HOLDINGS, INC.	+49.18%	14.14B
BIO-TECHNE CORPORATION	+3.45%	12.58B

Other Biotechnology & Medical Research